Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Director · Chief Executive Officer | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Actinium Pharmaceuticals, Inc.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,965,355 |
Ending reported balance
After 2026-09-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-02 · Grant · Acquired 753,600 · Balance 938,081 F1: Represents a grant of restricted stock units ("RSUs"). These RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant. Row 2 · 2026-09-02 · Grant · Acquired 1,027,274 · Balance 1,965,355 F2: Represents a grant of RSUs. These RSUs vest fully on the third anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2036-09-02 | Direct | 1,130,400 |
Reported balance
After 2026-09-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-02 · Grant · Acquired 1,130,400 · Balance 1,130,400 F3: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). These RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant.
F2: Represents a grant of RSUs. These RSUs vest fully on the third anniversary of the date of grant.
F3: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 21:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 1,130,400 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097741 · ownership.xml · derivative · entry 3 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,130,400 Underlying: Common Stock · 1,130,400 shares Expires 2036-09-02 F3 · derivative.exercise_date: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 21:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantCommon Stock | 1,027,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097741 · ownership.xml · nonDerivative · entry 2 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,965,355 F2 · shares: Represents a grant of RSUs. These RSUs vest fully on the third anniversary of the date of grant. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 21:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantCommon Stock | 753,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097741 · ownership.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 938,081 F1 · shares: Represents a grant of restricted stock units ("RSUs"). These RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Tax withholdingCommon Stock | 120,900 | $1.71 | $206,739.00 |
DisclosureSEC source: 0001213900-25-079019 · ownership.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,481 F1 · shares: Represents shares of common stock withheld to pay Mr. Seth's tax withholding obligations incurred in connection with the vesting of 300,000 restricted stock units, or RSUs, on August 18, 2025. On August 17, 2022, Mr. Seth was granted an award of 300,000 RSUs, in exchange for warrants granted to Mr. Seth on December 17, 2012 for services provided to the Company prior to becoming employed by Actinium. The warrants were in the money since vesting on December 17, 2013. Mr. Seth refrained from exercising the warrants to be aligned with the long-term interests of the Company and stockholders. In November 2018, the Board extended the expiration of Mr. Seth's warrants to February 2022. In February 2022, the Company requested that Mr. Seth not exercise the warrants. In exchange, the Board determined to grant Mr. Seth 300,000 RSUs based on the average fair value of the warrants during their vested life to continue to align Mr. Seth with the long-term interest of the Company and stockholders. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 984,367 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-25-028226 · ownership.xml · derivative · entry 8 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 984,367 shares Expires 2033-12-28 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 827,366 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0001213900-25-028226 · ownership.xml · derivative · entry 7 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 827,366 shares Expires 2032-07-01 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 310,182 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001213900-25-028226 · ownership.xml · derivative · entry 6 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 310,182 shares Expires 2031-09-01 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 139,062 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001213900-25-028226 · ownership.xml · derivative · entry 5 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 139,062 shares Expires 2030-08-12 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.96 | $0.00 |
DisclosureSEC source: 0001213900-25-028226 · ownership.xml · derivative · entry 4 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-07-12 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 33,333 | $0.00 Strike: $23.49 | $0.00 |
DisclosureSEC source: 0001213900-25-028226 · ownership.xml · derivative · entry 3 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires 2028-07-13 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $41.70 | $0.00 |
DisclosureSEC source: 0001213900-25-028226 · ownership.xml · derivative · entry 2 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2027-03-14 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $59.70 | $0.00 |
DisclosureSEC source: 0001213900-25-028226 · ownership.xml · derivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,666 shares Expires 2026-04-15 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 22:17 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 984,367 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-23-100063 · ownership.xml · derivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 984,367 Underlying: Common Stock · 984,367 shares Expires 2033-12-28 F1 · derivative.exercise_price: This price represents the closing price of the Issuer's common stock on December 28, 2023, the date of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Issuer's 2019 Stock Plan, 2% of the options will vest each month from the date of grant until fully vested. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:55 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-049737 · ownership.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,381 Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 23:13 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 827,366 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0001213900-22-036868 · ownership.xml · derivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,366 Underlying: Common Stock · 827,366 shares Expires 2032-07-01 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:01 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 310,182 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001213900-21-046682 · ownership.xml · derivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,182 Underlying: Common Stock · 310,182 shares Expires 2031-09-01 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:21 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 139,062 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001213900-20-022341 · ownership.xml · derivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,062 Underlying: Common Stock · 139,062 shares Expires 2030-08-12 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 21:02 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 1,500,000 | $0.23 Strike: $0.23 | $348,000.00 |
DisclosureSEC source: 0001213900-19-012875 · ownership.xml · derivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2029-07-12 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 21, 2019 21:45 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherCommon Stock | 8,125 | $0.60 | $4,875.00 |
DisclosureSEC source: 0001213900-19-002982 · ownership.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,458 Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 21:14 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon Stock | 10,000 | $0.44 | $4,372.00 |
DisclosureSEC source: 0001213900-18-017145 · ownership.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,333 Read SEC document |
| July 17, 2018 Filed Jul 17, 2018 21:13 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon stock | 10,000 | $0.79 | $7,900.00 |
DisclosureSEC source: 0001213900-18-009317 · ownership.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,333 Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:13 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 1,000,000 | $0.78 Strike: $0.78 | $782,900.00 |
DisclosureSEC source: 0001213900-18-009317 · ownership.xml · derivative · entry 2 SETH SANDESH · CIK 0001566175 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| April 19, 2018 Filed Apr 20, 2018 20:15 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon Stock | 5,000 | $0.38 | $1,900.00 |
DisclosureSEC source: 0001213900-18-004773 · f4041918seth_actiniumpharma.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,333 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:35 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherSeries B Warrants · Derivative | 39,375 | $0.50 Strike: $0.70 | $19,687.50 |
DisclosureSEC source: 0001213900-18-002739 · f4030618seth_actiniumpharm.xml · derivative · entry 3 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 39,375 shares Expires 2020-09-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:35 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherSeries A Warrants · Derivative | 13,125 | $0.50 Strike: $0.60 | $6,562.50 |
DisclosureSEC source: 0001213900-18-002739 · f4030618seth_actiniumpharm.xml · derivative · entry 2 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 13,125 shares Expires 2019-03-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:35 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherCommon Stock | 52,500 | $0.50 | $26,250.00 |
DisclosureSEC source: 0001213900-18-002739 · f4030618seth_actiniumpharm.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,333 Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 20:35 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon Stock | 33,333 | $0.75 | $24,999.75 |
DisclosureSEC source: 0001213900-17-008254 · f4080217seth_actiniumpharm.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,833 Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 20:54 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon Stock | 5,000 | $1.16 | $5,800.00 |
DisclosureSEC source: 0001213900-17-006529 · f4061517seth_actinium.xml · nonDerivative · entry 2 SETH SANDESH · CIK 0001566175 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 20:54 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon stock | 2,500 | $1.17 | $2,925.00 |
DisclosureSEC source: 0001213900-17-006529 · f4061517seth_actinium.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:36 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 750,000 | $1.39 Strike: $1.39 | $1,042,500.00 |
DisclosureSEC source: 0001213900-17-002469 · f4031417sandesh_actinium.xml · derivative · entry 5 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2027-03-14 F3 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 100,000 options are subject to cancellation based on the obtainment of certain milestones. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:36 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantWarrant to purchase common stock · Derivative | 57,212 | $2.34 Strike: $2.34 | $133,876.08 |
DisclosureSEC source: 0001213900-17-002469 · f4031417sandesh_actinium.xml · derivative · entry 4 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,212 Underlying: Common Stock · 57.212 shares Expires 2022-02-11 Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:36 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherWarrant to purchase common stock · Derivative | 57,212 | $2.34 Strike: $2.34 | $133,876.08 |
DisclosureSEC source: 0001213900-17-002469 · f4031417sandesh_actinium.xml · derivative · entry 3 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,212 shares Expires 2018-01-28 F2 · kind: Certain warrants were issued to Mr. Seth as part of investment banking and advisory services either prior to and outside of Mr. Seth's role as a Board Member and subsequently Executive Chairman and are not compensation for these latter services to the Company. The Executive Chairman has refrained from exercising certain warrants that are or have been in the money for most of their term in order to align with the long term interests of the Company. In order to maintain that alignment on March 14, 2017 the Company cancelled a Warrant in the amount of 57,212, shares and issued a new warrant with a term until February 11, 2022. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:36 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherWarrant to purchase common stock · Derivative | 99,619 | $0.78 Strike: $0.78 | $77,702.82 |
DisclosureSEC source: 0001213900-17-002469 · f4031417sandesh_actinium.xml · derivative · entry 2 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 99.619 Underlying: Common Stock · 99,619 shares Expires 2022-02-11 F1 · kind: Certain warrants were issued to Mr. Seth as part of investment banking and advisory services either prior to and outside of Mr. Seth's role as a Board Member and subsequently Executive Chairman and are not compensation for Board or Executive Chairman services to the Company. The Executive Chairman has refrained from exercising certain warrants that are or have been in the money for most of their term in order to align with the long term interests of the Company. In order to maintain that alignment on March 14. 2017, the warrant was amended to extend the term until February 11, 2022. The warrant issued for 99,619 shares was issued to Amrosan LLC, an entity affiliated with Mr. Seth's family. F1 · ownership.nature: Certain warrants were issued to Mr. Seth as part of investment banking and advisory services either prior to and outside of Mr. Seth's role as a Board Member and subsequently Executive Chairman and are not compensation for Board or Executive Chairman services to the Company. The Executive Chairman has refrained from exercising certain warrants that are or have been in the money for most of their term in order to align with the long term interests of the Company. In order to maintain that alignment on March 14. 2017, the warrant was amended to extend the term until February 11, 2022. The warrant issued for 99,619 shares was issued to Amrosan LLC, an entity affiliated with Mr. Seth's family. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:36 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherWarrant to purchase common stock · Derivative | 64,746 | $0.78 Strike: $0.78 | $50,501.88 |
DisclosureSEC source: 0001213900-17-002469 · f4031417sandesh_actinium.xml · derivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,746 Underlying: Common Stock · 64.746 shares Expires 2022-02-11 F1 · kind: Certain warrants were issued to Mr. Seth as part of investment banking and advisory services either prior to and outside of Mr. Seth's role as a Board Member and subsequently Executive Chairman and are not compensation for Board or Executive Chairman services to the Company. The Executive Chairman has refrained from exercising certain warrants that are or have been in the money for most of their term in order to align with the long term interests of the Company. In order to maintain that alignment on March 14. 2017, the warrant was amended to extend the term until February 11, 2022. The warrant issued for 99,619 shares was issued to Amrosan LLC, an entity affiliated with Mr. Seth's family. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 13:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon stock | 5,000 | $0.88 | $4,400.00 |
DisclosureSEC source: 0001213900-17-000008 · f4123016seth_actiniumphar.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Read SEC document |
| December 12, 2016 Filed Dec 12, 2016 21:44 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon stock | 5,000 | $0.98 | $4,900.00 |
DisclosureSEC source: 0001213900-16-019329 · f4121216sandesh_actiniumphar.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.